US investors refrained from purchasing

On Monday, December 9, key stock indices of the United States of America finished trading in negative territory, taking a short pause after a significant growth session earlier.
Post image
In the absence of vital macroeconomic statistics, bidders focused on M&A events. In addition, investors' attention this week will be directed to the outcome of the meeting of the European Central Bank and the Fed Open Market Committee.
The concern is caused by continuing uncertainty in trade negotiations between China and the United States. The parties have repeatedly stated that the first phase of the trade agreement may be signed soon, but this has not yet happened. Moreover, an important date is approaching. It is likely that if the deal is not signed before December 15, the United States will introduce an additional 15 percent tariff on imports of goods from China of $156 billion.
At the end of the session, the Dow Jones Industrial Average blue-chip indicator dipped 0.38% to 27909.60 points, the S&P 500 wide market index fell 0.32% to 3135.96 points, and the Nasdaq index of high-tech companies decreased by 0.40% and closed at 8621.83 points.
Futures for Light crude oil for delivery in January following the trading on the NYMEX fell $0.18 to $59.02 a barrel. As a result of trading on COMEX, the price of gold futures for delivery in February fell by $ 0.20 to $ 1,464.90 per troy ounce. The yield on ten-year treasury bonds, in turn, was 1.83%.
The market capitalization of the pharmaceutical company Merck & Co (NYSE: MRK) decreased by 0.15% after it announced the acquisition of ArQule for $2.7 billion. ArQule securities recovered by 103.9%.
Synthorx, which specializes in caring for patients with cancer and autoimmune diseases, was among the favorites of the auction, adding 170.52% to its asset due to the news that the French pharmaceutical company Sanofi (PA: SASY) agreed to purchase it for $2. 5 billion
Shares of the United States' most significant health insurance company UnitedHealth Group (NYSE: UNH) lowered by 0.95% due to claims that its OptumRx division would acquire Diplomat Pharmacy for $4 per share.
To get more information about the latest global economic news, visit GMOTrading.com.

Comments

Popular posts from this blog

The Fed directed $70.2 billion in Short-Term liquidity into markets

Perfect reading matter: top 5 books of 2018 by Bill Gates

Samsung showed bending smartphone Fold and new flagships S10